The short answer
The sources do not show that ropinirole changes your need for kava or establish a safe timing interval. Kava guidance advises against combining it with sedative substances, so discuss it with your prescriber before use.
What this answer covers
Oral Piper methysticum products; extraction method and composition vary.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- ropinirole
Review the combination before focusing on timing
Kava guidance advises against use with sedative substances, and ropinirole can cause sudden sleep episodes. Taking the products at different times has not been shown to prevent impairment.
Benefit is not assured
In a four-week trial, the kava group did not improve its primary anxiety outcome more than placebo. The trial did not test ropinirole and does not establish safety of the combination.
The exact kava product matters
Kava has been linked to rare severe liver injury across different preparation types. That is a kava safety concern, not proof of added liver toxicity from ropinirole. Bring the full product information to the treating team.
When daytime sleepiness needs attention
Contact your prescriber promptly for new marked daytime sleepiness or falling asleep during ordinary activities. Do not drive or use machinery if this occurs. Ropinirole can cause sleep episodes even without a warning feeling of drowsiness; the treating team should decide how to change treatment.
Evidence and practical considerations
Side effects & toxicity
A precaution about combined impairment is reasonable, but changed kava requirements or protective dose spacing is not demonstrated.
- Exact scope
- Oral Piper methysticum products; extraction method and composition vary. with Oral immediate-release ropinirole, with hydrochloride salt expressed as equivalent free base in label section 11.
- Medication form and route
- oral
- Timing or duration
- No exact-pair safe duration or protective spacing interval established.
What remains uncertain
- No exact-pair trial; kava safety guidance and efficacy evidence are separate from ropinirole interaction measurements.
Factors that may matter: baseline alertness; exact preparation; other medicines; treatment indication.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral immediate-release ropinirole tablets for Parkinson disease or primary restless legs syndrome.
Ropinirole can cause somnolence, sudden sleep episodes and orthostatic hypotension. Concomitant sedating medicines or alcohol can increase sleepiness risk. CYP1A2 is its major metabolic enzyme; inhibitors and inducers may alter clearance. Ciprofloxacin increased exposure, whereas theophylline did not. Cigarette smokers had lower dose-normalized exposure than nonsmokers in a small RLS comparison.
How this applies: Exact oral ropinirole risk and metabolic context; section 11 justifies hydrochloride-to-free-base active-moiety identity only.
No direct study of these six supplement combinations. Immediate-release tablet context does not establish release-form or dose interchangeability.
Source 2: official guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the specified supplement.
Advises against use with sedative substances. Kava may cause dizziness and has been linked to rare severe liver injury, including with different extraction methods.
How this applies: Preparation-specific context; not a directly measured ropinirole interaction.
Not a ropinirole study. Intrinsic liver risk does not establish added ropinirole hepatotoxicity; preparation and co-exposure vary.
Source 3: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 adults randomized to three groups in an internet-based trial.
Neither active intervention improved its primary anxiety or insomnia outcome more than placebo.
How this applies: Preparation-specific context; not a directly measured ropinirole interaction.
Not both active botanicals together, not ropinirole co-use. Accessible abstract does not fully characterize dose and preparation; efficacy result is not proof of combination safety.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Targeted sources inspected and all current available claims adjudicated; no clinical review asserted. | |
| Research summary published |
Article revision: 709040b7a48e3803
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.